In this completed Phase 2 study, brilaroxazine met all safety endpoints with no weight gain, no increase in blood sugar and lipids, and no cardiac or endocrine adverse effects compared to placebo.
The small company has only one Phase 3 trial running and limited capital. I hope the Phase 3 results are good enough for an NDA.
The next step is to manufacture antipsychotics that do not act directly or indirectly (as utaront and karxt do) on the dopaminergic system. That will be the “big” breakthrough.